Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

The G Protein-Coupled Estrogen Receptor (GPER) Expression Correlates with Pro-Metastatic Pathways in ER-Negative Breast Cancer: A Bioinformatics Analysis.

Talia M, De Francesco EM, Rigiracciolo DC, Muoio MG, Muglia L, Belfiore A, Maggiolini M, Sims AH, Lappano R.

Cells. 2020 Mar 4;9(3). pii: E622. doi: 10.3390/cells9030622.

2.

Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approaches.

Turnbull AK, Selli C, Martinez-Perez C, Fernando A, Renshaw L, Keys J, Figueroa JD, He X, Tanioka M, Munro AF, Murphy L, Fawkes A, Clark R, Coutts A, Perou CM, Carey LA, Dixon JM, Sims AH.

BMC Bioinformatics. 2020 Jan 28;21(1):30. doi: 10.1186/s12859-020-3365-5.

3.

T-cell co-stimulation in combination with targeting FAK drives enhanced anti-tumor immunity.

Canel M, Taggart D, Sims AH, Lonergan DW, Waizenegger IC, Serrels A.

Elife. 2020 Jan 21;9. pii: e48092. doi: 10.7554/eLife.48092.

4.

Exercise Window Trial in Newly Diagnosed Breast Cancer-Letter.

Sims AH, Leggate M, Campbell A.

Clin Cancer Res. 2019 Dec 15;25(24):7609-7610. doi: 10.1158/1078-0432.CCR-19-2571. No abstract available.

PMID:
31836618
5.

Author Correction: MEG3 long noncoding RNA regulates the TGF-β pathway genes through formation of RNA-DNA triplex structures.

Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, Mitra S, Mohammed A, James AR, Hoberg E, Moustakas A, Gyllensten U, Jones SJM, Gustafsson CM, Sims AH, Westerlund F, Gorab E, Kanduri C.

Nat Commun. 2019 Nov 21;10(1):5290. doi: 10.1038/s41467-019-13200-7.

6.

Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer.

Inda MA, Blok EJ, Kuppen PJK, Charehbili A, den Biezen-Timmermans EC, van Brussel A, Fruytier SE, Meershoek-Klein Kranenbarg E, Kloet S, van der Burg B, Martens JWM, Sims AH, Turnbull AK, Dixon JM, Verhaegh W, Kroep JR, van de Velde CJH, van de Stolpe A.

Mol Cancer Ther. 2020 Feb;19(2):680-689. doi: 10.1158/1535-7163.MCT-19-0318. Epub 2019 Nov 14.

7.

Microenvironmental IL1β promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling.

Eyre R, Alférez DG, Santiago-Gómez A, Spence K, McConnell JC, Hart C, Simões BM, Lefley D, Tulotta C, Storer J, Gurney A, Clarke N, Brown M, Howell SJ, Sims AH, Farnie G, Ottewell PD, Clarke RB.

Nat Commun. 2019 Nov 1;10(1):5016. doi: 10.1038/s41467-019-12807-0.

8.

The Milk Protein Alpha-Casein Suppresses Triple Negative Breast Cancer Stem Cell Activity Via STAT and HIF-1alpha Signalling Pathways in Breast Cancer Cells and Fibroblasts.

Garner KEL, Hull NJ, Sims AH, Lamb R, Clarke RB.

J Mammary Gland Biol Neoplasia. 2019 Sep;24(3):245-256. doi: 10.1007/s10911-019-09435-1. Epub 2019 Sep 12.

PMID:
31529195
9.

Development of mouse models of angiosarcoma driven by p53.

Salter DM, Griffin M, Muir M, Teo K, Culley J, Smith JR, Gomez-Cuadrado L, Matchett K, Sims AH, Hayward L, Henderson NC, Brunton VG.

Dis Model Mech. 2019 Jul 9;12(7). pii: dmm038612. doi: 10.1242/dmm.038612.

10.

On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer.

Bownes RJ, Turnbull AK, Martinez-Perez C, Cameron DA, Sims AH, Oikonomidou O.

Breast Cancer Res. 2019 Jun 14;21(1):73. doi: 10.1186/s13058-019-1159-3.

11.

PAK4 regulates stemness and progression in endocrine resistant ER-positive metastatic breast cancer.

Santiago-Gómez A, Kedward T, Simões BM, Dragoni I, NicAmhlaoibh R, Trivier E, Sabin V, Gee JM, Sims AH, Howell SJ, Clarke RB.

Cancer Lett. 2019 Aug 28;458:66-75. doi: 10.1016/j.canlet.2019.05.014. Epub 2019 May 20.

12.

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer.

Loi S, Michiels S, Baselga J, Bartlett JMS, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Michael Dixon J, Piccart MJ, Sotiriou C.

PLoS One. 2019 Apr 23;14(4):e0216175. doi: 10.1371/journal.pone.0216175. eCollection 2019.

13.

Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets.

Cassetta L, Fragkogianni S, Sims AH, Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P, Lin EY, Fidanza A, Lopez-Yrigoyen M, Millar MR, Urman A, Ai Z, Spellman PT, Hwang ES, Dixon JM, Wiechmann L, Coussens LM, Smith HO, Pollard JW.

Cancer Cell. 2019 Apr 15;35(4):588-602.e10. doi: 10.1016/j.ccell.2019.02.009. Epub 2019 Mar 28.

14.

Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research.

Selli C, Sims AH.

Breast Cancer (Auckl). 2019 Feb 19;13:1178223419829072. doi: 10.1177/1178223419829072. eCollection 2019. Review.

15.

Pharmacological inhibition of the IKKε/TBK-1 axis potentiates the anti-tumour and anti-metastatic effects of Docetaxel in mouse models of breast cancer.

Bishop RT, Marino S, de Ridder D, Allen RJ, Lefley DV, Sims AH, Wang N, Ottewell PD, Idris AI.

Cancer Lett. 2019 May 28;450:76-87. doi: 10.1016/j.canlet.2019.02.032. Epub 2019 Feb 18.

16.

Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer.

Bonello M, Sims AH, Langdon SP.

Cancer Biol Med. 2018 Nov;15(4):375-388. doi: 10.20892/j.issn.2095-3941.2018.0062.

17.

HER2 regulates HIF-2α and drives an increased hypoxic response in breast cancer.

Jarman EJ, Ward C, Turnbull AK, Martinez-Perez C, Meehan J, Xintaropoulou C, Sims AH, Langdon SP.

Breast Cancer Res. 2019 Jan 22;21(1):10. doi: 10.1186/s13058-019-1097-0.

18.

Molecular changes during extended neoadjuvant letrozole treatment of breast cancer: distinguishing acquired resistance from dormant tumours.

Selli C, Turnbull AK, Pearce DA, Li A, Fernando A, Wills J, Renshaw L, Thomas JS, Dixon JM, Sims AH.

Breast Cancer Res. 2019 Jan 7;21(1):2. doi: 10.1186/s13058-018-1089-5.

19.

Immune Cell Gene Signatures for Profiling the Microenvironment of Solid Tumors.

Nirmal AJ, Regan T, Shih BB, Hume DA, Sims AH, Freeman TC.

Cancer Immunol Res. 2018 Nov;6(11):1388-1400. doi: 10.1158/2326-6066.CIR-18-0342. Epub 2018 Sep 28.

20.

Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.

Baxter DE, Kim B, Hanby AM, Verghese ET, Sims AH, Hughes TA.

Clin Breast Cancer. 2018 Dec;18(6):481-488. doi: 10.1016/j.clbc.2018.07.002. Epub 2018 Jul 6.

21.

Regulation of breast cancer induced bone disease by cancer-specific IKKβ.

Marino S, Bishop RT, Capulli M, Sophocleous A, Logan JG, Mollat P, Mognetti B, Ventura L, Sims AH, Rucci N, Ralston SH, Idris AI.

Oncotarget. 2018 Mar 23;9(22):16134-16148. doi: 10.18632/oncotarget.24743. eCollection 2018 Mar 23.

22.

Epigenome-wide SRC-1-Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer.

Ward E, Varešlija D, Charmsaz S, Fagan A, Browne AL, Cosgrove N, Cocchiglia S, Purcell SP, Hudson L, Das S, O'Connor D, O'Halloran PJ, Sims AH, Hill AD, Young LS.

Clin Cancer Res. 2018 Aug 1;24(15):3692-3703. doi: 10.1158/1078-0432.CCR-17-2615. Epub 2018 Mar 22.

23.

MCL-1 is a prognostic indicator and drug target in breast cancer.

Campbell KJ, Dhayade S, Ferrari N, Sims AH, Johnson E, Mason SM, Dickson A, Ryan KM, Kalna G, Edwards J, Tait SWG, Blyth K.

Cell Death Dis. 2018 Jan 16;9(2):19. doi: 10.1038/s41419-017-0035-2.

24.

Kindlin-1 Promotes Pulmonary Breast Cancer Metastasis.

Sarvi S, Patel H, Li J, Dodd GL, Creedon H, Muir M, Ward J, Dawson JC, Lee M, Culley J, Salter DM, Sims AH, Byron A, Brunton VG.

Cancer Res. 2018 Mar 15;78(6):1484-1496. doi: 10.1158/0008-5472.CAN-17-1518. Epub 2018 Jan 12.

25.

Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations.

Hollis RL, Meynert AM, Churchman M, Rye T, Mackean M, Nussey F, Arends MJ, Sims AH, Semple CA, Herrington CS, Gourley C.

BMC Cancer. 2018 Jan 3;18(1):16. doi: 10.1186/s12885-017-3981-2.

26.

GPER mediates the angiocrine actions induced by IGF1 through the HIF-1α/VEGF pathway in the breast tumor microenvironment.

De Francesco EM, Sims AH, Maggiolini M, Sotgia F, Lisanti MP, Clarke RB.

Breast Cancer Res. 2017 Dec 6;19(1):129. doi: 10.1186/s13058-017-0923-5.

27.

Nuclear FAK and Runx1 Cooperate to Regulate IGFBP3, Cell-Cycle Progression, and Tumor Growth.

Canel M, Byron A, Sims AH, Cartier J, Patel H, Frame MC, Brunton VG, Serrels B, Serrels A.

Cancer Res. 2017 Oct 1;77(19):5301-5312. doi: 10.1158/0008-5472.CAN-17-0418. Epub 2017 Aug 14.

28.

Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast.

Martínez-Pérez C, Turnbull AK, Ekatah GE, Arthur LM, Sims AH, Thomas JS, Dixon JM.

Cancer Treat Rev. 2017 Apr;55:163-172. doi: 10.1016/j.ctrv.2017.03.009. Epub 2017 Mar 31. Review.

PMID:
28402908
29.

WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel.

Artibani M, Sims AH, Slight J, Aitken S, Thornburn A, Muir M, Brunton VG, Del-Pozo J, Morrison LR, Katz E, Hastie ND, Hohenstein P.

Sci Rep. 2017 Mar 27;7:45255. doi: 10.1038/srep45255.

30.
31.

Differential expression of store-operated calcium- and proliferation-related genes in hepatocellular carcinoma cells following TRPC1 ion channel silencing.

Selli C, Pearce DA, Sims AH, Tosun M.

Mol Cell Biochem. 2016 Sep;420(1-2):129-40. doi: 10.1007/s11010-016-2776-0. Epub 2016 Jul 22.

32.

Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies.

Pearce DA, Arthur LM, Turnbull AK, Renshaw L, Sabine VS, Thomas JS, Bartlett JM, Dixon JM, Sims AH.

Sci Rep. 2016 Jul 7;6:29434. doi: 10.1038/srep29434.

33.

Intermittent energy restriction induces changes in breast gene expression and systemic metabolism.

Harvie MN, Sims AH, Pegington M, Spence K, Mitchell A, Vaughan AA, Allwood JW, Xu Y, Rattray NJ, Goodacre R, Evans DG, Mitchell E, McMullen D, Clarke RB, Howell A.

Breast Cancer Res. 2016 May 28;18(1):57. doi: 10.1186/s13058-016-0714-4.

34.

Identification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.

Creedon H, Gómez-Cuadrado L, Tarnauskaitė Ž, Balla J, Canel M, MacLeod KG, Serrels B, Fraser C, Unciti-Broceta A, Tracey N, Le Bihan T, Klinowska T, Sims AH, Byron A, Brunton VG.

Oncotarget. 2016 Mar 8;7(10):11539-52. doi: 10.18632/oncotarget.7317.

35.

Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors.

Varešlija D, McBryan J, Fagan A, Redmond AM, Hao Y, Sims AH, Turnbull A, Dixon JM, Ó Gaora P, Hudson L, Purcell S, Hill AD, Young LS.

Clin Cancer Res. 2016 Jun 1;22(11):2765-77. doi: 10.1158/1078-0432.CCR-15-1583. Epub 2016 Jan 13.

36.

Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.

Serrels A, Lund T, Serrels B, Byron A, McPherson RC, von Kriegsheim A, Gómez-Cuadrado L, Canel M, Muir M, Ring JE, Maniati E, Sims AH, Pachter JA, Brunton VG, Gilbert N, Anderton SM, Nibbs RJ, Frame MC.

Cell. 2015 Sep 24;163(1):160-73. doi: 10.1016/j.cell.2015.09.001.

37.

Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.

Simões BM, O'Brien CS, Eyre R, Silva A, Yu L, Sarmiento-Castro A, Alférez DG, Spence K, Santiago-Gómez A, Chemi F, Acar A, Gandhi A, Howell A, Brennan K, Rydén L, Catalano S, Andó S, Gee J, Ucar A, Sims AH, Marangoni E, Farnie G, Landberg G, Howell SJ, Clarke RB.

Cell Rep. 2015 Sep 29;12(12):1968-77. doi: 10.1016/j.celrep.2015.08.050. Epub 2015 Sep 17.

38.

MEG3 long noncoding RNA regulates the TGF-β pathway genes through formation of RNA-DNA triplex structures.

Mondal T, Subhash S, Vaid R, Enroth S, Uday S, Reinius B, Mitra S, Mohammed A, James AR, Hoberg E, Moustakas A, Gyllensten U, Jones SJ, Gustafsson CM, Sims AH, Westerlund F, Gorab E, Kanduri C.

Nat Commun. 2015 Jul 24;6:7743. doi: 10.1038/ncomms8743. Erratum in: Nat Commun. 2019 Nov 21;10(1):5290.

39.

Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.

Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, Dunbier AK, Thomas JS, Dowsett M, Sims AH, Dixon JM.

J Clin Oncol. 2015 Jul 10;33(20):2270-8. doi: 10.1200/JCO.2014.57.8963. Epub 2015 Jun 1.

40.

Monocytes and macrophages, implications for breast cancer migration and stem cell-like activity and treatment.

Ward R, Sims AH, Lee A, Lo C, Wynne L, Yusuf H, Gregson H, Lisanti MP, Sotgia F, Landberg G, Lamb R.

Oncotarget. 2015 Jun 10;6(16):14687-99.

41.

Loss of TGFβ Receptor Type 2 Expression Impairs Estrogen Response and Confers Tamoxifen Resistance.

Busch S, Sims AH, Stål O, Fernö M, Landberg G.

Cancer Res. 2015 Apr 1;75(7):1457-69. doi: 10.1158/0008-5472.CAN-14-1583.

42.

Gene expression profiling reveals biological pathways responsible for phenotypic heterogeneity between UK and Sri Lankan oral squamous cell carcinomas.

Saeed AA, Sims AH, Prime SS, Paterson I, Murray PG, Lopes VR.

Oral Oncol. 2015 Mar;51(3):237-46. doi: 10.1016/j.oraloncology.2014.12.004. Epub 2015 Jan 2.

PMID:
25560800
43.

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

Arthur LM, Turnbull AK, Renshaw L, Keys J, Thomas JS, Wilson TR, Lackner MR, Sims AH, Dixon JM.

Breast Cancer Res Treat. 2014 Aug;147(1):211-9. doi: 10.1007/s10549-014-3080-x. Epub 2014 Aug 9.

PMID:
25104442
44.

Molecular changes in lobular breast cancers in response to endocrine therapy.

Arthur LM, Turnbull AK, Webber VL, Larionov AA, Renshaw L, Kay C, Thomas JS, Dixon JM, Sims AH.

Cancer Res. 2014 Oct 1;74(19):5371-6. doi: 10.1158/0008-5472.CAN-14-0620. Epub 2014 Aug 6.

45.

Increased STAT1 signaling in endocrine-resistant breast cancer.

Huang R, Faratian D, Sims AH, Wilson D, Thomas JS, Harrison DJ, Langdon SP.

PLoS One. 2014 Apr 11;9(4):e94226. doi: 10.1371/journal.pone.0094226. eCollection 2014.

46.

Engineering a synthetic cell panel to identify signalling components reprogrammed by the cell growth regulator anterior gradient-2.

Gray TA, Alsamman K, Murray E, Sims AH, Hupp TR.

Mol Biosyst. 2014 Jun;10(6):1409-25. doi: 10.1039/c4mb00113c. Epub 2014 Apr 7.

PMID:
24710632
47.

A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity.

Ablett MP, O'Brien CS, Sims AH, Farnie G, Clarke RB.

Oncotarget. 2014 Feb 15;5(3):599-612.

48.

Decreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.

Lehn S, Tobin NP, Sims AH, Stål O, Jirström K, Axelson H, Landberg G.

BMC Cancer. 2014 Feb 22;14:119. doi: 10.1186/1471-2407-14-119.

49.

Modulation of strain-specific differences in gene expression by cannabinoid type 2 receptor deficiency.

Sophocleous A, Sims AH, Idris AI, Ralston SH.

Calcif Tissue Int. 2014 Apr;94(4):423-32. doi: 10.1007/s00223-013-9823-6. Epub 2013 Dec 27.

PMID:
24370613
50.

Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression.

Keune WJ, Sims AH, Jones DR, Bultsma Y, Lynch JT, Jirström K, Landberg G, Divecha N.

Cancer Res. 2013 Dec 1;73(23):6913-25. doi: 10.1158/0008-5472.CAN-13-0424. Epub 2013 Oct 14.

Supplemental Content

Support Center